ESC 365 - Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice

ESC Premium Access

Evaluation of appropriate use and clinical outcomes of idarucizumab as antidote of dabigatran in daily clinical practice

Session: Poster Session 3 - Atrial fibrillation - Stroke prevention

Topic: Oral Anticoagulation

Speaker: Mr S. van der Wall (Haarlem, NL)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Mr Sake van der Wall

Spaarne Gasthuis, Haarlem (Netherlands (The))

0 follower

10 more presentations in this session

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study

Speaker: Doctor X. Li (Princeton, US)

Age threshold for ischemic stroke risk in atrial fibrillation: cohort data covering the entire Korean population

Speaker: Assistant Professor H. Yu (Seoul, KR)

Antiplatelet therapy use in atrial fibrillation patients taking oral anticoagulation: an analysis of adverse outcomes from the FANTASIIA registry.

Speaker: Doctor M. Esteve Pastor (Murcia, ES)

The new warfarin dosing algorithm for patients with atrial fibrillation and severe chronic kidney disease

Speaker: Doctor Z. Salpagarova (Moscow, RU)

Serum light-chain neurofilament, a brain lesion marker, correlates with CHA2DS2-VASc score among patients with atrial fibrillation: a cross-sectional study

Speaker: Doctor S. Aeschbacher (Basel, CH)

Access the full session

Poster Session 3 - Atrial fibrillation - Stroke prevention

Speakers: Mr S. van der Wall, Doctor X. Li, Assistant Professor H. Yu, Doctor M. Esteve Pastor, Doctor Z. Salpagarova...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources